CD274 and triple-negative breast carcinoma: Currently, atezolizumab, a monoclonal antibody that targets PD-L1, was approved in combination with nab-paclitaxel for patients with unresectable locally advanced triple-negative breast cancer (TNBC) or metastatic TNBC expressing PD-L1 [7, 8].